Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Target Price at $66.00

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned a consensus rating of “Buy” from the eleven analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $66.00.

Several research firms have commented on MAZE. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Wedbush increased their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. Truist Financial decreased their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. HC Wainwright increased their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Finally, Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $26.03 on Monday. Maze Therapeutics has a 1 year low of $8.24 and a 1 year high of $53.65. The firm’s 50-day moving average is $35.79 and its two-hundred day moving average is $38.14. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -8.06 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08. On average, equities analysts expect that Maze Therapeutics will post -2.59 earnings per share for the current year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the sale, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $266,461.11. This represents a 41.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total transaction of $441,900.00. Following the sale, the chief marketing officer directly owned 15,000 shares of the company’s stock, valued at approximately $441,900. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 70,000 shares of company stock valued at $2,955,775. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Large investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its position in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.